Potential applications of nanoparticles in cancer immunotherapy

Download
  1. Get@NRC: Potential applications of nanoparticles in cancer immunotherapy (Opens in a new window)
DOIResolve DOI: http://doi.org/10.1080/21645515.2016.1245251
AuthorSearch for: ; Search for: ; Search for: ; Search for:
TypeArticle
Journal titleHuman Vaccines & Immunotherapeutics
ISSN2164-5515
2164-554X
Volume13
Issue1
Pages6374
Subjectcancer; delivery system; immunotherapy; immunomodulation; nanoparticles
AbstractIn recent years considerable progress has been made in the field of cancer immunotherapy whereby treatments that modulate the body's own immune system are used to combat cancer. This has the potential to not only elicit strong anti-cancer immune responses which can break pre-existing tolerance and help promote tumor regression, but could also induce immunological memory which may help prevent tumor recurrence. In order to ensure effective delivery of immunotherapeutic agents, such as vaccines, checkpoint inhibitors, chemotherapeutic agents and nucleic acids, a safe and effective delivery system is often required. One such approach is the use of multifunctional nanoparticles (NPs), such as liposomes, polymers, micelles, dendrimers, inorganic NPs, and hybrid NPs, which have the potential to combine the delivery of a diverse range of therapeutic immunomodulators thereby increasing the efficacy of tumor cell killing. This review focuses on recent progress in NP-mediated immunotherapy for the treatment of cancer.
Publication date
PublisherTaylor & Francis
LanguageEnglish
AffiliationHuman Health Therapeutics; National Research Council Canada
Peer reviewedYes
NRC numberNRC-HHT-53322
NPARC number23001897
Export citationExport as RIS
Report a correctionReport a correction
Record identifier4a91f7f2-da99-49e0-a8aa-41ad974026d4
Record created2017-05-09
Record modified2017-05-09
Bookmark and share
  • Share this page with Facebook (Opens in a new window)
  • Share this page with Twitter (Opens in a new window)
  • Share this page with Google+ (Opens in a new window)
  • Share this page with Delicious (Opens in a new window)